Home - MakingPharmaIndustry

Business

Deal & Finance

Roche takes aim at inflammatory bowel disease

Simone Montonati - November 5, 2023

With its oncology drugs in decline and a string of recent failures on Alzheimer's, the Swiss giant veers into Inflammatory Bowel Diseases (IBD) by securing for more than 7 billion the U.S. rights to an investigational new drug.

Deal & Finance

Sanofi’s strategic turnaround

Simone Montonati - October 29, 2023

The French company has announced the spin-off of its consumer unit and increased investment in the development of new immunology and inflammation drugs, but must abandon its profit targets for the next two years

Goodbye NASH, it’s Alfasigma’s time

October 17, 2023

Agreement for antiviral biologics low cost production

March 8, 2022

Baxter and Hillrom: advancing healthcare together

December 20, 2021

Highly potent API expansion for Olon Rodano site

August 6, 2021

BIODRUGS & ATMP

BioDrugs & ATMP

62° AFI Symposium – Maria Luisa Nolli’s interview

Carolina Martinelli - May 15, 2023

ONE HEALTH

Clinical research

DARWIN EU: towards easy and secure access to health data

Redazione - July 18, 2023

DARWIN EU, acronym for Data Analysis and Real World Interrogation Network, is the new long-term project of EMA, the European Medicines Agency. The objective...